Primer: CANbridge Pharmaceuticals (1228 HK) - Mar 2026
CANbridge Pharmaceuticals is a biopharmaceutical company strategically focused on the high-growth rare disease market in China, with a mission...
196 Views
𝛼SK or SearchENTITY
CANbridge Pharmaceuticals (1228 HK)
CANbridge Pharmaceuticals (1228 HK)
8
Analysis
Health Care • China
CANbridge Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of transformative therapies for rare diseases and oncology. The company offers approved drugs such as Hunterase for Hunter syndrome and Livmarli for Alagille syndrome, and is developing a pipeline of gene therapies and other assets. It was founded in 2012 and is headquartered in Suzhou, China.
morex